The report highlights the company's commitment to creating value for patients, now and into the future. The company launched two new products in 2019: Evenity® and Nayzilam®, and obtained new approvals for treatments in Cimzia®. The company achieved revenues of € 4.9 billion, and net sales of € 4 680 million (€ 4 784 million excluding € -104 million hedging) across its core products and established brands in 2019.
Issuing Company UCB S.A.
Report Type Integrated Report
Report Language EN
Report Filesize 10.59 MB
No. of Pages 241 pages
Reporting periodJanuary 1, 2019-December 31, 2019
Report EditionUnknown
Assurance Provider Independent limited assurance
Reporting Standards GRI; Global Reporting Standards
Materiality Assessmenttrue
